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1.  Introduction
Previous chapters in this report have illustrated the potential 
of genomics to lead to important improvements in our 
understanding of health and in the diagnosis and treatment 
of disease. They have also suggested that the achievement 
of these benefits is going to require significant changes 
in the ways in which healthcare is understood, organised 
and practised in the NHS. One of the most important of 
these is the need for a greater degree of integration of, and 
complementarity between, healthcare and medical research. 
A second is a growth in the importance of the collection, 
storage and appropriate sharing of information at scale: 
in the care of individuals and families, in research, and in 
the improvement of health systems. A third will be the 
importance of a faster pace of learning and a consequently 
greater degree of uncertainty and open-endedness in 
healthcare practice. Each of these is going to have profound 
implications for the way the NHS works and for how the 
obligations and responsibilities of health professionals 
and institutions – as well as those of patients – are to be 
understood. Together, however, these changes have the 
potential to bring important benefits to patients and their 
families. 
The founders of the NHS were committed to two guiding 
principles.1 The first of these was to the availability of 
healthcare on the basis of need and independent of the 
ability to pay. The second, which is less widely discussed 
than the first, was that this health care should be of a very 
high standard of excellence. The value of the first is clearly 
enhanced by that of the second. Development of genomics 
and its integration into day-to-day practice of the NHS has 
the potential to provide important improvements to the 
quality of care provided equitably by the NHS, but the pace of 
development and the need for large scale data interpretation 
mean that research and innovation will need to become more 
integral to routine NHS practice than we have seen to date.  
In this chapter, we reassert the importance of these 
important founding principles of the NHS and argue that if 
the potential benefits of genomics are to be realised, there 
is a need for a rethinking of the wider ‘social contract’ for 
medical practice and research in the UK.* After introducing 
and discussing the social contract and its importance, we 
go on to identify and discuss four areas to which we believe 
particular attention needs to be paid. The first of these is 
consent. The second is the use of information in the care and 
treatment of both patients and their relatives. The third is 
the need to rethink the duties and responsibilities of health 
professionals, and the fourth concerns the responsibilities of 
health systems in the context of rapid developments outlined 
in previous chapters.
*    In this chapter we use the term ‘social contract’. In similar discussions 
others have sometimes used the term ‘social license’. We prefer the 
term social contract because of its helpful implication of the location 
of healthcare and medical research in a broader context of social 
arrangements, practices and institutions.
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2.  Rethinking the social  
contract for medical  
care and research
The NHS Constitution reminds us that our health service is 
founded on a common set of principles and values that bind 
together patients, the public and staff in order to ensure 
that it can be effective and equitable. It recognises that each 
party has important rights that must be respected, but also 
that each owes each other responsibilities. Through this 
combination of reciprocal rights and obligations the NHS 
aims to operate fairly and effectively for mutual benefit. 
The NHS Constitution is thus the expression of a form of 
‘social contract’ which aims to bring the highest levels of 
human knowledge and skill to save lives and improve health. 
We need to understand and agree how those rights and 
responsibilities work in genomics if we are to harness its 
potential to fulfill the promise that the NHS “is there to 
improve our health and well-being, supporting us to keep 
mentally and physically well, to get better when we are ill 
and, when we cannot fully recover, to stay as well as we can 
to the end of our lives”.2
Under this social contract, the health service has important 
responsibilities. We feel safe in entrusting our bodies and 
intimate personal information to health professionals in 
part because of the rights we have to protect our ourselves 
through the giving or withholding of consent, in part because 
we have confidence that those staff will act with integrity 
in our interests – for example in maintaining high standards 
of confidentiality – and in part because there are systems 
in place that protect our interests and hold professionals 
to account. In the era of genomic medicine the basis of 
this contract needs to be revisited. Most obviously, this is 
because linking up of large data-systems containing personal 
identifiable data,† on a scale not previously necessary 
(or possible), is a prerequisite for success, but also because 
genomics will provide both diagnoses and predictions and 
will affect patients, families, the general public in different 
ways over time.
Whilst it is clear from earlier chapters in this report that 
genomics has the potential to bring great benefits to 
patients, there has been considerable, and understandable, 
public concern over the handling of personal data by the 
NHS,3 coupled with suspicion over the involvement of 
commercial organisations in the handling of ‘big data’.4 
A recent survey commissioned by the Wellcome Trust on 
commercial access to data suggests that the public see 
genomics as both of great potential benefit and as presenting 
important risks.5 The success of genomic medicine will 
depend on patients having confidence that the way genomic 
information is generated, held and used will properly protect 
their interests. This requires re-examining the traditional 
rules around confidentiality, which focused on secrecy 
and the keeping of information as separate and private. 
Such a rigid separation cannot operate in genomics, which 
requires clinicians to consider the patient’s specific genetic 
situation in comparison with knowledge gleaned from others. 
The most important structural implications of the move to 
genomic, big data-driven medicine is the requirement for a 
greater degree of interdependence between the care and 
treatment of individual patients on the one hand and the 
collection and analysis of data relating to the care of very 
large numbers of other patients, often in real time, on the 
other. The clinical interpretation of genome findings requires 
information about clinical features in others with similar 
findings:  the genotype-phenotype association remains 
an important clinical tool. Genomic medicine will require 
use of patient level information to support better clinical 
decisions in the future and for others. For this to be ethical, 
and acceptable to patients, a stronger focus on information 
security, data analysis and decision-support will be required 
as will greater clarity about and broad agreement on the 
relevant obligations of health professionals and systems.‡ 
†    In the past, research studies providing the data for health care 
improvement would either have been collected using specific consent, 
and or a non-identifiable form. Genomics raises problems with 
anonymization because the data cannot be completely anonymised 
and can result in identification of individuals. Attempts to deal with 
this issue through consent are problematic because of the wide range 
of possible outcomes, over time, from genomic research.
‡    In addition to the benefits to individuals of interpreting their 
information in the context of a larger dataset, there will also be 
situations in which information arising in the direct care of one 
person, can prove vital in informing the care of others e.g. where 
it leads to the identification of an infectious disease, or where it 
identifies others at high risk of a condition. Provision will also need to 
be made for dealing with such situations.
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As the Nuffield Council on Bioethics has suggested,6 
the successful and appropriate use of data-driven approaches 
to healthcare and research will require the NHS to provide 
the public with a mutually acceptable statement of the 
expectations that they can have of the use of data. 
This would need to include a realistic explanation of the 
ways in which genomic medicine can personalise care, 
addressing the sometimes excessive assumptions about the 
predictive or diagnostic power of genetics. It would require 
an explanation of how the management of data protects 
privacy, but necessarily uses information that cannot be 
completely anonymous because of the uniqueness of our 
genetic identities.§ It would need to recognise that one of 
the consequences of advances in genomic medicine is that 
initial consents to the use of genomic information cannot 
be fully informed about future uses or interpretations, and 
so there is a need for high standards of broad consent to be 
complemented by continuing oversight of the way genomic 
data is handled.
This needs to be coupled with assurances of the competence 
of the NHS to deliver on the information governance 
requirements of genomic medicine. People need to be able 
to trust it to hold data securely, make it available to clinicians 
reliably when needed for patient care, and to patients 
themselves in an intelligible manner. Current information 
systems in the NHS are unlikely to be sufficient to earn this 
level of trust since they often seem to operate on a tacit 
permission to continue until the public withdraws their 
support due to mistrust. Instead, people need to be satisfied 
that genomic medicine operates in their common interests, 
whilst protecting their individual privacy, and does not exploit 
some to benefit others. Protection of individual privacy 
cannot be absolute,** nor can data ever be guaranteed 
as entirely secure, but there needs to be an understanding 
of the associated risks and reassurance that breaches are 
appropriately prosecuted.  
The basis for greater trust and confidence created by such 
a social contract could encourage the growth of “genomic 
citizenship” or the genetic altruism and solidarity described 
by the Human Genetics Commission7: Genomics offers 
benefits and responsibilities for the individual, the family, 
the broader community and globally that cannot be realized 
by keeping the secrets revealed from one genome separate 
from others. 
This requires a mutuality that is not captured by current 
systems. The idea of a social contract provides a basis 
for such an arrangement because it endures over time, 
brings benefits (and obligations) for both patients and the 
professionals (and services) who offer care. To achieve this, 
processes for creating common understanding are required, 
as well as mechanisms for revising the agreement when 
necessary.8
§    Even though we differ in only roughly 0.1% of our genetic codes, 
this still equates to some 3 million variants.
**    We will also need to address how protection of privacy is related to 
identifiability of genomic information, i.e. just because a sequence 
is potentially identifiable because of its uniqueness, does not mean 
that the privacy of a person is more invaded than were the data truly 
anonymous.
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3.  Renegotiation of the social  
contract - reasons
3.1 Overview
We began this chapter by highlighting three key requirements 
for the achievement of the benefits of genomics in the 
NHS for patients and families. These were: a greater degree 
of integration and complementarity between research, 
innovation, and clinical practice; the collection, storage 
and more effective use of health data; and, a more central 
role for learning and open-endedness in day-to-day clinical 
practice. In what follows, and against this background, 
we discuss a selection of some of the key areas of medical 
practice and research in which new ways of thinking about 
and practising medicine – each an important element of the 
social contract - are going to need to be considered in the 
renegotiation of the social contract. They are: (1) consent, (2) 
confidentiality and caring for families, (3) the obligations of 
health professionals and researchers, (4) the appropriate uses 
of data and samples, and a range of governance and system 
responsibilities.
3.2 Valid consent
The obtaining of valid consent is an important part of good 
ethical practice in healthcare and research. Whilst consent 
is an important component of ethical practice, it is not in 
itself, however, a guarantor of high ethical standards. In 
genomics as elsewhere, consent needs to be understood 
as an important component of an ethics ecosystem along 
with, for example, the duties and obligations of health 
professionals to treat patients with respect and care, and 
the requirement for health systems to provide protections 
to ensure that those who provide their consent are not 
exploited, discriminated against or unfairly treated.
Consent is nonetheless an important part of good medical 
practice and high standards of consent are essential. In 
genomic medicine both the importance and the limits 
of consent become increasingly apparent. The wider 
introduction of genomics into medical practice will present 
significant challenges for the achievement of understanding. 
Many of the key concepts in genomics are both complex 
and likely to be new to many patients (as well as the health 
professionals offering them) and may present problems of 
explanation and understanding as will many of the features 
the healthcare system in which genomics plays a central 
role: the close relationship between research and clinical 
practice; the collection, storage and use of health data; 
and, the open-endedness and uncertainty at the heart of 
a learning healthcare system. These latter two factors will 
be important both at the time of consent and at the time 
of communication of results which may be revised over 
time as new evidence accumulates. There will often be a 
degree of uncertainty about findings and their current or 
future implications as well as uncertainty about the potential 
future research uses to which data may be put and what 
additional (or incidental) findings this may produce in the 
future. This uncertainty may be at the level of evidence 
available; more big data is needed to ensure that findings 
are reproducible, and that confidence limits are minimised. 
It may also be reflected in the fact that even where good 
evidence exists, the chances that the finding will result in a 
particular symptom or condition is uncertain because it may 
be just one factor in amongst several that determine whether 
the condition manifests. NHS health professionals will also 
need to improve their acknowledgement of such uncertainty, 
as too often the language of single highly penetrant gene 
mutations is used for susceptibility factors that may never 
manifest as signs or symptoms.
Case study 1
Results of genomic investigations in patients investigated 
for neuro-developmental delay (whose samples have 
been collected and stored in a national resource) reveal a 
mutation in a gene that increases the chance of a brain 
tumour. The relative risk that this mutation appears to 
confer is very high, but the absolute risk less than 15%. 
Records of the consent taken at the time of testing reveal 
no mention of the possibility of tumour/ cancer risks 
being found. Health professionals are concerned about 
disclosing this finding since no specific consent was given 
to find it. Some argue that the patients have a right to 
know about their increased risk, but others argue that 
the lack of clear evidence based interventions and the 
85% chance of not developing such a tumour would go 
against disclosure.  However, had consent been explicit 
about this possibility the health professionals would have 
disclosed regardless of ‘actionability’.
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The quality of consent needs to be sufficient to reflect the 
importance of respecting patients’ autonomy, but what 
kind of understanding of genomics is good enough for 
a decision to be seen as autonomous? This problem is 
sometimes presented as a problem about ‘broad consent’. 
To what extent can consent to participation can be thought 
to be genuine ‘consent’ where significant implications of the 
decision are unknown, or unknowable at the time? Can such 
consent meet the requirements for validity? How broad can 
consent be and still be valid, or indeed prevent claims of 
insufficient information, to make a decision? 
In this context, a key question is going to be how might the 
validity of consent be judged in contexts of such complexity 
and uncertainty? It is clearly not reasonable for the answer 
to be that consent to genomic testing, storage of the 
sample and communication of the data is only valid with 
‘full understanding’††. This would mean that the benefits 
of genomics could not be realised. It would also mean the 
imposition of a highly paternalistic approach to consent in 
which patients were not allowed to come to the conclusion 
– in the real world, against a background of significant 
uncertainty, that this is something they would like to pursue. 
All of this suggests a need not only for the development 
of new evidence-based approaches to best practice in 
consent but also a clearer statement of the complementary 
roles of consent and of other protections. It is our view that 
an important question should be what protections and 
controls need to be in place such that when people do give 
their valid consent – inevitably on the basis of a degree of 
uncertainty and open-endedness - they are not exploited, 
discriminated against or unfairly treated. 
It is also going to be important to consider what function 
consent is required to play, given the familial aspects of 
some genetic findings. Unlike an operation or procedure 
where there is a physical intrusion for which the operator 
requires consent, consent to genomic testing may perhaps 
be better seen as being explicit about entering a relationship 
with agreed ground rules about mutual responsibilities and 
rights. These mutual responsibilities and rights extend to the 
individual, their relatives who may be unwitting ‘stakeholders’ 
in the outcome of genomic testing and to the population as 
a whole who stand to benefit from largescale geno[me]type/ 
pheno[me]type correlations. 
Finally, it may be that the challenges presented by the 
uncertainties and open-endedness of genomic medicine 
require a rethinking of some aspects of the role of  
non-directedness in the doctor-patient relationship. It may, 
for example, turn out to be the case that patients are more 
likely to be content with the decisions they have made 
where the process of decision making involves a greater 
degree of clinician involvement/deliberation than is the 
case elsewhere. So whilst the genome ‘sequencing’ is a 
technical step, that can be undertaken with minimal medical 
intervention (spitting into a pot and sending it through the 
post) the complexity of the possible outcomes of analysis 
may require an extended clinical interaction to ensure that 
different types of outcomes (clear/ uncertain, mild/ severe, 
current or future) are assimilated in the consent process 
in a more clinician directed way than would normally 
be expected.  Might this, perhaps, be a place where the 
evidence reveals joint decision-making comes to be seen as 
‘better’ (by patients) than one that is more ‘non-directive’?
††    This is of course also true for existing care outside of genomics. 
The difficulties in promoting ‘full understanding’ are rarely 
acknowledged in policy documents, but have been examined  
by N. Manson and O. O’Neill ‘Rethinking Informed Consent in 
Bioethics’ (2007).
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3.3 Confidentiality and the availability of the 
best care for patients and families
High standards of confidentiality and the securing of 
potentially sensitive health care information are going to be 
at the heart of good genomic medicine practice. However, 
there are at least two important ways in which patients and 
the public are likely to be supportive of new practices in the 
use of patient information, each of which suggests the need 
for new thinking on the appropriate uses of health-related 
information and their limits:
The first of these relates to the potential benefits for 
individual patients of having at least some of their clinical 
data analysed together with genetic findings from others in 
population-scale (secure) data bases so that evidence can be 
acquired on the nature of the link between genotype and 
phenotype. This might improve their own care, now, in the 
future and improve the care of others. 
Case study 2
A mutation in the BRCA1 gene was thought for many 
years to confer a high risk of breast and ovarian cancer. 
More recently, evidence suggests that it is a benign 
variant and that the surveillance and interventions 
offered to those with the variant were therefore wrongly 
directed. This evidence has only come to light through 
international efforts and database linkages of family 
history details and segregation of the variant with 
disease in families. Although those with the variant have 
previously been advised they are at high risk, they, their 
relatives and future individuals can now receive more up 
to date clinical advice.
Source   See for example, E.T. Rosenthal, et al, ‘Exceptions to the rule: 
Case studies in the prediction of pathogenicity for genetic 
variants in hereditary cancer genes’, Clinical Genetics 2015
The second situation when the sharing of patient information 
in new ways might be expected to command support is to 
distinguish individual clinical information about a disease 
or condition from the inherited mutation(s) that led to the 
clinical findings. Whilst professional guidelines such as those 
from the GMC9 specifically list genetic information as one 
possible reason for breaching individual confidence (if doing 
so would protect people from serious harm), it might in 
certain cases also be possible to share relevant information 
without any breach of confidence. In practice, it is not always 
necessary to disclose to relatives (existing or future ones) that 
a specific patient has been diagnosed with, say, inherited 
breast cancer. They can be informed that in a particular 
family there is an inherited tendency to cancer that could 
be usefully tested for in family members who are worried 
about their risk. On some occasions, the second approach 
might raise concerns that discussing the test would identify 
a particular family member and constitute a breach of her or 
his confidentiality but this need not always, or even often, 
be the case – particularly in large or multi-generational 
families where others have the familial disease in question. 
For example, a woman who is concerned about her family 
history might simply be offered an appropriate genetic test 
without this raising any confidentiality concerns about the 
individual in whom the familial cause was first identified. 
We would argue that where this is the case, a social contract 
that would allow such information to be available for use 
by clinicians in the appropriate care of family members 
(for example, testing for the particular familial mutation to 
determine if extra surveillance is warranted) would be publicly 
acceptable.‡‡ Although this involves the use of information 
beyond the individual care of the person, this approach 
would only use familial information and not disclose any 
individual details thus maintaining confidentiality.  
‡‡    See for example, Confidentiality and sharing genetic information with 
relatives. Lucassen A, Parker M. Lancet 2010 May 1;375(9725):1507-9. 
Genetic information: a joint account? Parker M, Lucassen AM.BMJ. 
2004 Jul 17;329(7458):165-.
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Case study 3
A man with a mutation in a mismatch repair gene 
resulting in a high lifetime chance of bowel and other 
cancers steadfastly refuses to inform his siblings, or 
allow his doctor to do so, of the risk they might be at. 
The health care professionals know that one sister has 
had bowel cancer and is therefore likely to harbour the 
same mutation. This sister is at increased lifetime risk of 
endometrial cancer and might therefore benefit from a 
risk reducing hysterectomy. The heritable aspect of the 
cancer is insufficiently common to justify testing unless 
there is a family connection. Unless we allow the use of 
the familial information, we have to choose between 
either testing everyone, for little clinical utility in most 
cases, and at a cost to the NHS, or not testing at all. 
The health professionals have 3 options (1) to respect the 
man’s wishes (2) to breach his confidence on the basis 
that it is justified by the opportunity to prevent harm to 
relatives who might unknowingly have the mutation as 
per GMC guidelines (3) Use NHS tracing to contact the 
sister’s GP and tell him/her that a referral to a genomic 
service is recommended because she might be at 
increased risk. Option (3) does not need to breach the 
man’s confidence because only information that is familial 
is communicated.
One way forward therefore is for the boundaries of 
confidentiality in genomics to be seen, at least in some 
situations, at a familial rather than individual level. 
Taking a recent court case (ABC vs St Georges10) as an 
example, it may indeed not have been good practice for 
clinicians to tell the daughter that her father had the genetic 
condition, Huntington’s disease without his consent, but it 
might have been perfectly good practice to tell her that the 
facts of his case, and his family history – both which were in 
the public domain - indicated a potential familial risk about 
which she could seek independent advice and treatment. 
This separation of approaches to confidentiality of individual 
clinical information from familial genetic information has not 
yet gained widespread traction in practice, in part because 
of the limited situations to date where it was required, and 
in part because in some situations communication about 
familial information could lead to inference about individual 
clinical information. Evidence from qualitative research on 
the topic suggests that although health professionals find 
thinking in a familial way about genetic information difficult, 
many patients assume such an approach is happening and 
are surprised to hear that sharing and familial use are not 
standard practice.11 This suggests that there may be patient 
and public support for an approach adapting  the default 
position on confidentiality such that: Instead of breaching 
confidence only if one can prove they are preventing serious 
harm in specific others (current GMC guidance), the default 
becomes that relevant  information that might prevent harm 
is communicated  unless there are good reasons not to. 
There will, inevitably be some situations of a different kind in 
which the question of using of properly confidential patient 
information in the care of family members will need to be 
considered. Confidentiality is an extremely important part 
of good medical practice. The provision of evidence based 
medical advice and treatment requires patients to undergo 
tests and to entrust confidential information to professionals. 
Confidentiality also shields patients from embarrassments 
and intrusions into their private lives. Protecting patients’ 
confidences is as important in genomics as any other area of 
medicine. However, since certain genomic information may 
also be relevant for others, for example, biological relatives, 
or be dependent on data from them before it becomes 
information, there is a higher degree of interdependence in 
the generation of information than most areas of medicine. 
The principles of confidentiality and data protection therefore 
require special attention in this context, especially as the 
scope of genetic and genomic testing increases. 
On the one hand genomic findings may convey or predict 
sensitive, potentially stigmatising facts, on the other 
hand much genomic information is common to many, 
and particularly common to that of biological relatives. 
The information generated in circumstances of confidence 
to one person, may allow inferences to be drawn about its 
significance to another, whose views may, or may not be 
known. Conversely, inferences about a particular genomic 
output may only be possible if confidential information is first 
obtained from others. These aspects of genomics can mean 
that health care professionals do not know whether they are 
balancing their duties of confidentiality with the rights and 
freedoms of others appropriately. This needs to be borne in 
mind when calls for better data sharing between laboratories 
and countries are made. Data is most useful if linked to some 
clinical information and those submitting the data need to be 
clear what is acceptable within the rules of data protection 
and confidentiality. This is captured in the idea of ‘fair 
processing principles’ which can be developed through the 
elaboration of a new social contract for genomic medicine.
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Case study 4
Communication is not good between the different family 
members of one family at risk of sudden cardiac death 
through a pathogenic gene mutation that alters cardiac 
repolarization. Although information letters about the 
condition, the risks and the surveillance and treatments 
available have been given to the index patient in whom 
the mutation was found, it is clear that these have not 
been passed on. When another member of the family is 
referred for assessment of his family history of sudden 
cardiac death, health professionals are unsure whether 
utilizing the genetic result of the index patient in this 
assessment would breach his confidence. Whilst it would 
be inappropriate to reveal the clinical details of this index 
patient, telling the family member that there is reason to 
believe he might be at risk of a heritable mutation, is not.
 
 
One way in which such situations might be preempted is 
through the obtaining of consent at an early stage for the use 
of such information for the caring of family members as well 
as for submission to (inter)national databases for the benefit 
of wider family or other families. Through consent, patients 
can authorize the use of their confidential information for 
other purposes, including research and the treatment of 
others, and it may be appropriate to take steps to encourage 
patients to adopt this form of altruism or ‘genetic solidarity’ 
as a routine step in genomic medicine, or a social contract for 
confidentiality.12 Whilst much clarity can be achieved by such 
encouragement and explicit ‘up-front’ statements, there will 
be times when consideration needs to be given to whether 
it might be legitimate to use the information in question 
without specific consent. GMC guidelines on the limits 
of confidentiality with respect to genetic information9 are 
helpful in clarifying this possibility, but increasingly genomic 
testing is creating situations where the wishes of an individual 
are not known, and not easy to obtain, yet a result - perhaps 
not anticipatable at the time of testing - is relevant to others. 
As genomics reaches into many more areas of routine 
medical practice, consideration will need to be given as to 
whether conventional notions of a duty of confidentiality are 
realistic or appropriate and how genomic findings of different 
kinds ought to be dealt with. 
3.4 The obligations of health professionals, 
laboratory staff and researchers
Genomic medicine will have implications for what it means 
to be a good and ethical health professional in the NHS.  
It is likely that careful thought is going to be required on 
the question of how are we understand the obligations of 
doctors to their patients in this new world e.g. in the context 
of greater uncertainty, evolving knowledge and ongoing 
feedback, and a greater concern for the care of families. 
The clinical use of genomics is likely to take place in the 
context of a greater degree of interdependence between 
clinical practice and research, the collection and use of 
large datasets, and a much greater emphasis on ways of 
improving understanding and interpretation through the 
on-going refreshing of datasets with new data in real time. 
It will be increasingly difficult to argue that research and 
clinical ethics involve separate sets of principles, a distinction 
on which many current professional guidelines are based. 
Originally, the Declaration of Helsinki denied the acceptability 
of ‘therapeutic’ or ‘clinical’ research by professionals on 
their patients unless direct benefit to them was expected. 
Since, 2000 there has been a slight relaxation, with additional 
safeguards applied in the category of research combined with 
care, but maintaining a clear separation between the two.13 
Article 14 now recognises that research may be permissible 
provided that harm is avoided. It states that ‘Physicians who 
combine medical research with medical care should involve 
their patients in research only to the extent that this is 
justified by its potential preventive, diagnostic or therapeutic 
value and if the physician has good reason to believe that 
participation in the research study will not adversely affect 
the health of the patients who serve as research subjects’.14 
However, rapidly developing medical practices, and 
particularly genomics, will force us to revisit these positions 
since these areas involve research and care being alloyed 
together so that each activity is dependent on the other. 
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This also works the other way around. It means that 
researchers and data managers may increasingly come to be 
seen to have responsibilities that cannot easily or completely 
be divorced from clinical care. As the clinical predictions from 
genomics become clearer, it will become the norm rather 
than the exception that research will produce information 
that has potential clinical significance. It will be important 
to clarify when researchers are expected to liaise with 
clinicians, and which clinicians they should contact. Novel 
ways of linking research laboratories with clinical teams and 
quality assurance approved laboratories for validation will be 
important for effective interaction between research findings 
and clinical practice. 
In relation to clinical care, the level of detail of stratified and 
personalised medicine means that the resources to support 
decision-making and underpin evidence-based care will be 
different. Randomised controlled trials the gold standard 
evidence generating tool in many areas of medicine, will 
be more difficult to employ. Evidence about a particular 
genomic finding will require large scale (often across national 
boundaries) phenotype-genotype correlation that take 
ancestral genomic background and environmental factors 
into account. Nuanced yet uncertain diagnoses or predictions 
will remain the norm in genomics for the bulk of clinical 
practice over the next few years. Yet this is in the face of 
a discourse about genomics that often mixes appropriate 
claims of technological accuracy with claims about their 
clinical predictions which remain far less deterministic than 
commonly perceived. This will require judgment to play a 
greater role, something that is consistent with the origins 
of the evidence based medicine (EBM) movement but has 
become less prominent.15 This recognition of the importance 
of the subjective views of patients on what is material to 
their decisions in a 2015 UK Supreme Court decision in 
Montgomery vs Lanarkshire (2015) will need to be examined 
in the wake of genomic medicine’s possibilities including its 
uncertain predictions.16   
3.5 System responsibilities 
These issues cannot be resolved by individual clinicians, 
but need to be addressed collectively through the appropriate 
design of health systems.
Case study 5
A large study of whole genome sequences reveals a series 
of ‘pathogenic’ mutations in a sample of well individuals 
who took part in sequencing in order to make the search 
for a diagnosis in a relative more effective. Questions are 
raised about whose responsibility it is to communicate 
this information, how the downstream implications for 
the NHS in terms of clinical follow up, surveillance and 
treatment are managed, and how the evolving evidence 
about the predictive value of these mutations in terms of 
disease can best be communicated and by whom.
Decisions on whether such contact should be made require 
complex analysis and awareness of the ethics of risk 
communication. It seems unreasonable to place that burden 
on primary care alone. Provision needs to be made by the 
health service for analytical capacity and ethics support to 
advise researchers on when contact might be appropriate 
and clinicians on the significance of the information and how 
best to communicate it without causing confusion. It will also 
be important to establish when contact should be expected, 
and the NHS could be held liable for failing to seek to achieve 
it. For example, what level of risk, certainty or medical 
interventions would need to be available for lack of contact 
to be negligent and who would judge? When might contact 
be a discretionary matter and how could this respect 
potential rights not to know? It would be inappropriate 
to create legal obligations beyond those of fair and non-
discriminatory processes. If we are to achieve a consistent 
service, these issues will need to be tackled at a health system 
level not on individual clinical or research responsibilities. 
In any event, NHS clinical services and research studies are 
not currently resourced to be able to take on this role. 
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Further, if we recognise both the importance of consent 
and its limitations as a guarantor of ethical practice, and that 
genomic medicine challenges conventional approaches 
to confidentiality in significant ways, then a key question 
becomes what complementary protections and controls 
need to be in place such that when people do give their 
valid (but inevitably imperfect) consent, they are not 
exploited, discriminated against, unfairly treated and have 
their privacy unacceptably encroached upon. If, furthermore, 
we acknowledge that even where health professionals 
and laboratory staff perform their duties to the best of 
their ability there may be structural or institutional factors 
affecting the care of patients and the protection of their 
interests, this suggests a need to think carefully about the 
responsibilities of systems. That is, the responsibilities beyond 
those of individual health professionals, research groups or 
hospitals. 
Such responsibilities are likely to include questions relating 
to appropriate and accountable governance, oversight,  
data-security and where required, regulation. The ability 
of the NHS to show that it can be trusted on these issues 
will be an important foundation for the reasonableness of 
the new social contract that we propose. It will need to create 
systems that ensure widespread sharing of linked genomic 
data that helps interpret the patient’s specific information. 
This will necessarily originally be derived from individuals, 
but will need to be (a) available in a way that obscures 
identities where possible, (b) be subject to information 
governance safeguards. This is unlikely to be achievable 
in a fragmented provider system without national  
co-ordination. It may also require specific legislative authority.
However, it will also be important to establish clear 
responsibilities for ensuring equitable, access to the benefits 
of genomic medicine In clinical guidelines and national 
commissioning standards. It will not be reasonable to expect 
people to accept the new social contract unless the health 
service accepts responsibilities for ensuring that the benefits 
will be available to all.
Finally, protections against unfair discrimination will 
need to be enhanced. The Human Genetics Commission 
recommended on a number of occasions that specific 
provision providing protection against discrimination on 
the basis of genetic characteristics should be introduced. 
This would play an important role in making the new social 
contract a reasonable one to propose.
Chapter title
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4. Conclusion
In this chapter we have outlined some of the ethical 
challenges presented by the greater use of genomics in 
the NHS. We began by noting that the realisation of the 
important benefits of developments in genomics for patients 
is going to require significant changes in the ways in which 
health care is understood, organised and delivered. We 
picked out three particular aspects as having particular 
significance: the greater integration and complementarity 
between research and clinical practice; the central importance 
of data collection and analysis; and, the increasing role of 
uncertainty and open-endedness in genomic medicine. 
Against this backdrop, we have argued that the sustainable 
achievement of the benefits of genomics requires a broad 
renegotiation of the social contract for medical research and 
medical practice in the NHS. We picked out four areas in 
which this is likely to be particularly important: (1) consent; (2) 
confidentiality and the care of family members; (3) the duties 
and obligations of health professionals including laboratory 
staff; and, (4) system responsibilities and governance. There 
are a number of other important issues we could have 
discussed. Perhaps the most important of these concern the 
use of health data for research, and the potential importance 
of commercial companies in such research. Beyond the 
immediate clinical uses of data, the quality of care and the 
quality of knowledge about disease and treatments will be 
greatly improved by encouraging research activity on the 
data. Much progress is going to require the involvement 
of commercial and technology partners. If it is accepted 
that such activities are in the public interest and are a 
necessary condition for the NHS to meet its commitment 
to improvements in the diagnoses and treatments available 
to patients, careful thought is going to need to be given 
to the question of how this can be achieved in a way that 
commands public trust and contributes to, rather than 
undermine, higher standards of equitably available health 
care. Despite their importance, we have not discussed these 
issues at great length in this chapter because they are already 
the subject of a great deal of academic and policy debate.
The working out and agreement of the terms of any such 
contract requires the active involvement of many stakeholders 
including patients, health professionals, researchers, policy-
makers, and wider society. This suggests a key role for 
public engagement and involvement. Evidence suggests that 
members of the public are aware that genomics has the 
potential for great benefit but that its use presents a number 
of risks and challenges. Whilst the risks cannot be entirely 
eradicated it is reasonable to expect that given certain 
safeguards and adequate oversight there will be strong 
public support for the development of a health service with  
dynamic  genomics and the effective use of health data at its 
heart. 
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